Data cannot be shared publicly due to ethical restrictions on sharing data publicly. The protocol of this project (Research on the Positioning of Chronic Kidney Disease in Specific Health Check and Guidance in Japan) determined that analytical data were distributed only to the members of steering committee to avoid any possibility that someone else identify individuals of this cohort. Because the data contain potentially identifying information (i.e. prefectural number and date of health checking), our institutional ethics committee has imposed them. Also, data had been obtained with the protocol approved by the relevant institutional ethical review board. Data are available upon request, please contact Department of Chronic Kidney Disease Initiatives; Fukushima Medical University School of Medicine; 1-Hikarigaoka, Fukushima 960-1295, Japan; Phone & Fax: +81-24-547-1898; E-mail <dckdi@fmu.ac.jp>.

Introduction {#sec001}
============

Chronic kidney disease (CKD) is a risk factor for not only progression to end-stage kidney disease (ESKD), but also the development of cardiovascular disease (CVD) and all-cause mortality \[[@pone.0223005.ref001]--[@pone.0223005.ref007]\]. One recent cross-sectional study of a CKD population with CVD (34.7%) and malignant neoplasms (31.8%) as the leading causes of death demonstrated that a decline in the estimated glomerular filtration rate (eGFR) was associated with a higher risk of death due to CVD, but not malignancy \[[@pone.0223005.ref008]\]. Another study of a general population showed a slightly higher overall cancer mortality in CKD patients compared with non-CKD patients (adjusted hazard ratio \[HR\] 1.20 with a 95% confidence interval \[CI\] of 1.01--1.42) \[[@pone.0223005.ref009]\]. However, these investigations did not take variations in renal function and proteinuria into consideration.

Recently, the annual decline of the glomerular filtration rate (GFR) has been noted to be a risk factor for the development of ESKD and of CVD \[[@pone.0223005.ref010]--[@pone.0223005.ref014]\], and the change in eGFR is becoming a promising surrogate marker for clinical endpoints \[[@pone.0223005.ref010]--[@pone.0223005.ref017]\]. Moreover, the change in the albumin creatinine ratio (ACR) in urine is also considered a predictor for the incidence of CKD and of ESKD \[[@pone.0223005.ref018],[@pone.0223005.ref019]\]. Compared to stable ACR, a 4-fold increase in ACR was associated with more than 1.5-times higher risk of all-cause mortality, CVD mortality and non-CVD mortality, respectively. It was also found that a 4-fold decrease in ACR seemed to be associated with higher CVD mortality (HR \[95% CI\], 1.35 \[0.93--1.95\]), while the HR for non-CVD mortality was not higher (0.89 \[0.67--1.18\]). These results were not significant for various possible reasons, but they implied that a change in the amount of urinary albumin or protein might be associated with cause-specific death during follow-up.

When calculating ΔeGFR, fluctuation of measured-creatinine values considerably affects transient decreases and increases in eGFR, and we should carefully categorize low-eGFR to avoid non-CKD by examining creatinine twice with an appropriate interval \[[@pone.0223005.ref020]--[@pone.0223005.ref023]\]. Moreover, persistent proteinuria by consecutive dipstick urinalysis should be used, because more than half of positive dipstick proteinuria turns negative in the general population \[[@pone.0223005.ref024]\]. Analyses with a definitive diagnosis of CKD intensified the differences in risk of advancing renal dysfunction and mortality between CKD and non-CKD populations \[[@pone.0223005.ref020]--[@pone.0223005.ref023]\]. However, the significance of a transient diagnosis (ie, false-positive) of CKD with consecutive assessments both of eGFR and of proteinuria was not fully demonstrated in a clinical epidemiology study with a general population-based cohort.

We hypothesized that a transient diagnosis of CKD indicates a significantly higher mortality compared to definitive non-CKD as the negative control and lower mortality compared with definitive CKD as the positive control. The present study evaluated a longitudinal, general population cohort of 338,094 persons who received annual health checkups, including more than two assessments of proteinuria and renal function, according to "The Specific Health Check and Guidance in Japan" program in 2008, and their course and cause of death, coded according to the International Classification of Diseases, 10th revision (ICD-10), were followed for a median of 4.3 years from the first measurement of eGFR. These analyses confirmed the significant risk of all-cause mortality and CVD mortality in definitive CKD with persistent proteinuria, with G3a in women or G3b in men, and further highlighted the CVD-specific mortality risk of transient proteinuria.

Methods {#sec002}
=======

Study population {#sec003}
----------------

This longitudinal, cohort study was conducted according to the guidelines of the Declaration of Helsinki and was granted ethics approval by the relevant institutional review board (University of Tsukuba for ethical issues approved as No. 999, UMIN: 000019774). The study was performed as part of the prospective ongoing "Research on the Positioning of Chronic Kidney Disease in Specific Health Check and Guidance (so-called "Tokutei-Kenshin") in Japan" project. Other details, such as the participants' areas of residence, were reported previously \[[@pone.0223005.ref025]\]. The database was solely used and managed by the statistician, and the principal analyses to identify those of the screened subjects who died were completed by December 2018. Subsequent analyses were done using a standard analysis file (SAF) without any personal identifiers. The data included information about age, sex, body mass index (BMI), systolic blood pressure, diastolic blood pressure, smoking habit, and use of antihypertensive drugs, lipid-lowering drugs, and hypoglycemic drugs (obtained via self-reported questionnaire), the results of dipstick urinalysis for proteinuria and serological testing for serum creatinine concentration, and serum lipid status.

Mortality surveillance {#sec004}
----------------------

The underlying causes of death were coded according to ICD-10. Follow-up was conducted through December 2014. Cardiovascular mortality was defined as death due to circulatory diseases including myocardial infraction, heart failure, stroke, or sudden cardiac death reported as the 1st position cause of death (any ICD-10 code from the I chapter), as reported previously \[[@pone.0223005.ref019],[@pone.0223005.ref025]\]. Cancer mortality was defined as death due to a neoplasm reported as C00-D48.

Measurement of parameters {#sec005}
-------------------------

Urinalysis by the dipstick method was performed on a single spot-urine specimen. In Japan, the Japanese Committee for Clinical Laboratory Standards (<http://jccls.org/>) recommends that all urine dipstick results of 1+ correspond to a urinary protein level of 30 mg/dl; proteinuria was defined as 1+ or greater. In addition, blood samples were collected and assayed in an automatic clinical chemistry analyzer within 24 h of collection. Serum creatinine was measured using the enzymatic method. GFR was calculated using the formula of the Japanese Society of Nephrology \[[@pone.0223005.ref026]\]. CKD was defined as persistent positive proteinuria or reduced eGFR \<60 ml/min/1.73 m^2^ both at the first measurement and the second measurement with an interval of more than one year. Hypertension was defined as systolic blood pressure ≥140 mm Hg and diastolic blood pressure ≥90 mmHg. Hypercholesterolemia was defined as low-density lipoprotein ≥140 mg/dl, high-density lipoprotein cholesterol ≤40 mg/dl, or triglycerides ≥200 mg/dl. These co-morbid conditions at the baseline year were used in the risk analysis.

Statistical analysis {#sec006}
--------------------

The primary outcomes for the analysis were all-cause, CVD, and cancer deaths during the follow-up period. Variables were age, sex, hypertension, proteinuria, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, triglycerides, cigarette smoking, use of antihypertensive medications, use of lipid-lowering drugs, and treatment for diabetes. The hypertension category was developed according to blood pressure levels (normal, \<140/\<90 mm Hg; hypertensive, ≥140/≥90 mm Hg) and use of antihypertensive medications. Mean- or median values and contingencies were first compared between definitive non-CKD (negative/negative for proteinuria and for reduced eGFR) and another category of CKD diagnosis, using Student's *t*-test, Mann-Whitney's test, the chi-squared test, or one-way ANOVA, as appropriate. Mean values and standard deviations are shown in each table. Hazard ratios (HRs) of the incidence of CVD by sex were estimated using the Cox regression model (SAS version 9.4, SAS Institute, Cary, NC, USA). A *P* value of \<0.05 was considered significant.

Results {#sec007}
=======

A total of 664,926 subjects were screened, and the net subject population comprised 338,094 people (58.8% \[n = 198,921\] were women) who were aged from 40 to 74 years and for whom all of the data necessary for our research purposes were available ([Fig 1A](#pone.0223005.g001){ref-type="fig"}). Since the screened subjects had been examined with or without dipstick urinalysis and/or serum creatinine, 99.8% and 87.7% of screened subjects had at least one result for dipstick protein and eGFR, respectively. Similarly, 67.8% and 51.0% of the screened subjects had two or more results for them during the study period ([Fig 1B](#pone.0223005.g001){ref-type="fig"}). The study duration from the first measurement day of serum creatinine was 1 to 7 years (2008 through 2014, median 51 months, [Fig 1C](#pone.0223005.g001){ref-type="fig"}).

![Study design.\
**A**. Strategy of recruitment of the study population, follow-up, and outcome analyses. Two annual measurements either of proteinuria or of serum creatinine enable definitive diagnosis of chronic kidney disease (CKD). **B**. Subject number having checked dipstick proteinuria and serum creatinine with various frequencies in this study population. The white bars mean all healthcheck participants, and the gray bars indicate their proportions with at least one measurement. Subjects with more than one check (ie, 2 to 7 times) represented by the black bars were recruited. **C**. The histograms present all healthcheck participants (black line) and the study population included in survival analyses (black filled). Abbreviations: CKD, chronic kidney disease.](pone.0223005.g001){#pone.0223005.g001}

[Table 1](#pone.0223005.t001){ref-type="table"} shows the comparisons of baseline characteristics among the subpopulations having definitely negative proteinuria (-/- \[first measurement/second measurement\]), transient proteinuria (+/-), newly developed proteinuria (-/+), and definitive CKD with persistent proteinuria (+/+) in men and in women, respectively. The population having definitely negative proteinuria was the largest (88.6% in men and 94.0% in women), and their eGFR decrease was -0.4 ml/min/1.73 m^2^ between the first and second measurements. Subjects with transient proteinuria accounted for 3.8% of men and 2.3% of women, and they had older age, higher blood pressure, rate of using antihypertensive drugs and hypoglycemic drugs, worse dyslipidemia, rate of smoking, and BMI, and they had a lower eGFR. These characteristics were significant but milder than the subjects with persistent proteinuria.

10.1371/journal.pone.0223005.t001

###### Demographics of the study population with and without definitive CKD determined by proteinuria.

![](pone.0223005.t001){#pone.0223005.t001g}

  ------------------------------- -------------------------------------------- ------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------
                                                                               Men                                                                                                                         
  Proteinuria category            (first measurement) / (second measurement)   (-) / (-)     (+) / (-)                                              (-) / (+)                                              (+) / (+)
  Study size                      (persons)                                    123248        5347                                                   5750                                                   4828
  Age                             (years)                                      63 ± 8        63 ± 8[\*\*](#t001fn003){ref-type="table-fn"}          64 ± 8[\*\*\*](#t001fn004){ref-type="table-fn"}        65 ± 7[\*\*\*](#t001fn004){ref-type="table-fn"}
  Systolic blood pressure         (mmHg)                                       130 ± 17      135 ± 18[\*\*\*](#t001fn004){ref-type="table-fn"}      134 ± 17[\*\*\*](#t001fn004){ref-type="table-fn"}      139 ± 17[\*\*\*](#t001fn004){ref-type="table-fn"}
  Diastolic blood pressure        (mmHg)                                       78 ± 11       80 ± 11[\*\*\*](#t001fn004){ref-type="table-fn"}       79 ± 11[\*\*\*](#t001fn004){ref-type="table-fn"}       81 ± 11[\*\*\*](#t001fn004){ref-type="table-fn"}
  Use of antihypertensive drugs   (%)                                          30.9          44.3[\*\*\*](#t001fn004){ref-type="table-fn"}          45.8[\*\*\*](#t001fn004){ref-type="table-fn"}          60.5[\*\*\*](#t001fn004){ref-type="table-fn"}
  Use of hypoglycemic drugs       (%)                                          5.9           9.9[\*\*\*](#t001fn004){ref-type="table-fn"}           11.5[\*\*\*](#t001fn004){ref-type="table-fn"}          21.9[\*\*\*](#t001fn004){ref-type="table-fn"}
  Triglycerides                   (mg/dl)                                      136 ± 99      149 ± 117[\*\*\*](#t001fn004){ref-type="table-fn"}     150 ± 117[\*\*\*](#t001fn004){ref-type="table-fn"}     165 ± 124[\*\*\*](#t001fn004){ref-type="table-fn"}
  Low-density lipoprotein         (mg/dl)                                      120 ± 30      120 ± 32                                               118 ± 31[\*\*\*](#t001fn004){ref-type="table-fn"}      121 ± 32[\*\*](#t001fn003){ref-type="table-fn"}
  High-density lipoprotein        (mg/dl)                                      57.2 ± 15.1   56.2 ± 15.4[\*\*\*](#t001fn004){ref-type="table-fn"}   55.6 ± 15.1[\*\*\*](#t001fn004){ref-type="table-fn"}   54.2 ± 15.4[\*\*\*](#t001fn004){ref-type="table-fn"}
  Use of lipid-lowering drugs     (%)                                          10.4          13.2[\*\*\*](#t001fn004){ref-type="table-fn"}          14.3[\*\*\*](#t001fn004){ref-type="table-fn"}          20.6[\*\*\*](#t001fn004){ref-type="table-fn"}
  Smoking                         (%)                                          24.4          27.7[\*\*](#t001fn003){ref-type="table-fn"}            28.6[\*\*\*](#t001fn004){ref-type="table-fn"}          29.1[\*\*\*](#t001fn004){ref-type="table-fn"}
  Body mass index                 (kg/m^2^)                                    23.7 ± 3.0    24.4 ± 3.5[\*\*\*](#t001fn004){ref-type="table-fn"}    24.3 ± 3.3[\*\*\*](#t001fn004){ref-type="table-fn"}    25.2 ± 3.5[\*\*\*](#t001fn004){ref-type="table-fn"}
  Estimated GFR, first year       (ml/min/1.73 m^2^)                           75.1 ± 15.3   73.0 ± 17.8[\*\*\*](#t001fn004){ref-type="table-fn"}   73.8 ± 17.3[\*\*\*](#t001fn004){ref-type="table-fn"}   65.9 ± 20.0[\*\*\*](#t001fn004){ref-type="table-fn"}
  Estimated GFR, second year      (ml/min/1.73 m^2^)                           74.7 ± 15.3   73.3 ± 18.1[\*\*\*](#t001fn004){ref-type="table-fn"}   71.7 ± 17.5[\*\*\*](#t001fn004){ref-type="table-fn"}   63.7 ± 20.9[\*\*\*](#t001fn004){ref-type="table-fn"}
                                                                               Women                                                                                                                       
  Proteinuria category            (first measurement) / (second measurement)   (-) / (-)     (+) / (-)                                              (-) / (+)                                              (+) / (+)
  Study size                      (persons)                                    186957        4521                                                   4877                                                   2566
  Age                             (years)                                      63 ± 8        64 ± 8[\*\*\*](#t001fn004){ref-type="table-fn"}        64 ± 8[\*\*\*](#t001fn004){ref-type="table-fn"}        65 ± 7[\*\*\*](#t001fn004){ref-type="table-fn"}
  Systolic blood pressure         (mmHg)                                       127 ± 17      132 ± 19[\*\*\*](#t001fn004){ref-type="table-fn"}      132 ± 18[\*\*\*](#t001fn004){ref-type="table-fn"}      137 ± 18[\*\*\*](#t001fn004){ref-type="table-fn"}
  Diastolic blood pressure        (mmHg)                                       75 ± 10       78 ± 16[\*\*\*](#t001fn004){ref-type="table-fn"}       77 ± 11[\*\*\*](#t001fn004){ref-type="table-fn"}       79 ± 11[\*\*\*](#t001fn004){ref-type="table-fn"}
  Use of antihypertensive drugs   (%)                                          26.0          40.5[\*\*\*](#t001fn004){ref-type="table-fn"}          39.9[\*\*\*](#t001fn004){ref-type="table-fn"}          56.3[\*\*\*](#t001fn004){ref-type="table-fn"}
  Use of hypoglycemic drugs       (%)                                          3.3           6.6[\*\*\*](#t001fn004){ref-type="table-fn"}           7.4[\*\*\*](#t001fn004){ref-type="table-fn"}           13.4[\*\*\*](#t001fn004){ref-type="table-fn"}
  Triglycerides                   (mg/dl)                                      110 ± 64      120 ± 76[\*\*\*](#t001fn004){ref-type="table-fn"}      120 ± 71[\*\*\*](#t001fn004){ref-type="table-fn"}      143 ± 95[\*\*\*](#t001fn004){ref-type="table-fn"}
  Low-density lipoprotein         (mg/dl)                                      129 ± 30      130 ± 32[\*](#t001fn002){ref-type="table-fn"}          129 ± 31                                               132 ± 32[\*\*\*](#t001fn004){ref-type="table-fn"}
  High-density lipoprotein        (mg/dl)                                      65.3 ± 15.8   63.2 ± 16.3[\*\*\*](#t001fn004){ref-type="table-fn"}   63.4 ± 16.2[\*\*\*](#t001fn004){ref-type="table-fn"}   60.8 ± 15.9[\*\*\*](#t001fn004){ref-type="table-fn"}
  Use of lipid-lowering drugs     (%)                                          18.6          23.0[\*\*\*](#t001fn004){ref-type="table-fn"}          23.9[\*\*\*](#t001fn004){ref-type="table-fn"}          30.2[\*\*\*](#t001fn004){ref-type="table-fn"}
  Smoking                         (%)                                          5.0           6.1                                                    6.8[\*\*](#t001fn003){ref-type="table-fn"}             6.6
  Body mass index                 (kg/m^2^)                                    22.7 ± 3.3    23.9 ± 4.2[\*\*\*](#t001fn004){ref-type="table-fn"}    23.7 ± 4.0[\*\*\*](#t001fn004){ref-type="table-fn"}    25.0 ± 4.5[\*\*\*](#t001fn004){ref-type="table-fn"}
  Estimated GFR, first year       (ml/min/1.73 m^2^)                           76.6 ± 15.9   74.2 ± 18.1[\*\*\*](#t001fn004){ref-type="table-fn"}   75.4 ± 18.4[\*\*\*](#t001fn004){ref-type="table-fn"}   67.5 ± 21.9[\*\*\*](#t001fn004){ref-type="table-fn"}
  Estimated GFR, second year      (ml/min/1.73 m^2^)                           76.2 ± 15.9   74.6 ± 18.7[\*\*\*](#t001fn004){ref-type="table-fn"}   73.5 ± 18.3[\*\*\*](#t001fn004){ref-type="table-fn"}   65.7 ± 22.7[\*\*\*](#t001fn004){ref-type="table-fn"}
  ------------------------------- -------------------------------------------- ------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------

Proteinuria was defined as 1+ or greater by dipstick tests.

\*P\<0.05,

\*\*P\<0.01, and

\*\*\*P\<0.001.

Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.

[Table 2](#pone.0223005.t002){ref-type="table"} shows the comparisons of baseline characteristics among the subpopulations with definitely not reduced eGFR below 60 ml/min/1.73 m^2^ (-/-), transiently reduced eGFR (+/-), newly reduced eGFR (-/+), and definitive CKD with permanently reduced eGFR (+/+) in men and in women, respectively. The population with definitely not reduced eGFR was the largest (77.1% in men and 84.1% in women). The subjects with transiently reduced eGFR accounted for 4.7% of men and 4.0% of women, and they had older age, higher systolic blood pressure and rate of using antihypertensive drugs, worse dyslipidemia, higher BMI, and lower eGFR. These characteristics were significant but milder than the subjects with permanently reduced eGFR.

10.1371/journal.pone.0223005.t002

###### Demographics of the study population with and without definitive CKD determined by eGFR.

![](pone.0223005.t002){#pone.0223005.t002g}

  ------------------------------- -------------------------------------------- ------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------
                                                                               Men                                                                                                                         
  Reduced eGFR category           (first measurement) / (second measurement)   (-) / (-)     (+) / (-)                                              (-) / (+)                                              (+) / (+)
  Study size                      (persons)                                    107261        6596                                                   7637                                                   17617
  Age                             (years)                                      62 ± 9        66 ± 6[\*\*\*](#t002fn004){ref-type="table-fn"}        65 ± 6[\*\*\*](#t002fn004){ref-type="table-fn"}        67 ± 5[\*\*\*](#t002fn004){ref-type="table-fn"}
  Systolic blood pressure         (mmHg)                                       130 ± 17      131 ± 16[\*](#t002fn002){ref-type="table-fn"}          133 ± 17[\*\*\*](#t002fn004){ref-type="table-fn"}      133 ± 17[\*\*\*](#t002fn004){ref-type="table-fn"}
  Diastolic blood pressure        (mmHg)                                       78 ± 11       78 ± 10                                                79 ± 11[\*\*\*](#t002fn004){ref-type="table-fn"}       79 ± 11[\*\*\*](#t002fn004){ref-type="table-fn"}
  Use of antihypertensive drugs   (%)                                          29.8          37.4[\*\*\*](#t002fn004){ref-type="table-fn"}          40.3[\*\*\*](#t002fn004){ref-type="table-fn"}          48.3[\*\*\*](#t002fn004){ref-type="table-fn"}
  Use of hypoglycemic drugs       (%)                                          6.4           6.6                                                    7.9                                                    9.2[\*\*\*](#t002fn004){ref-type="table-fn"}
  Triglycerides                   (mg/dl)                                      137 ± 103     139 ± 97                                               145 ± 113[\*\*\*](#t002fn004){ref-type="table-fn"}     141 ± 87[\*\*\*](#t002fn004){ref-type="table-fn"}
  Low-density lipoprotein         (mg/dl)                                      120 ± 30      122 ± 30[\*\*\*](#t002fn004){ref-type="table-fn"}      120 ± 30                                               122 ± 30[\*\*\*](#t002fn004){ref-type="table-fn"}
  High-density lipoprotein        (mg/dl)                                      57.6 ± 15.3   56.1 ± 14.9[\*\*\*](#t002fn004){ref-type="table-fn"}   55.3 ± 14.7[\*\*\*](#t002fn004){ref-type="table-fn"}   54.2 ± 14.3[\*\*\*](#t002fn004){ref-type="table-fn"}
  Use of lipid-lowering drugs     (%)                                          9.7           13.1[\*\*\*](#t002fn004){ref-type="table-fn"}          13.5[\*\*\*](#t002fn004){ref-type="table-fn"}          17.4[\*\*\*](#t002fn004){ref-type="table-fn"}
  Smoking                         (%)                                          26.9          17.3[\*\*\*](#t002fn004){ref-type="table-fn"}          21.3[\*\*\*](#t002fn004){ref-type="table-fn"}          16.0[\*\*\*](#t002fn004){ref-type="table-fn"}
  Body mass index                 (kg/m^2^)                                    23.6 ± 3.1    24.1 ± 2.9[\*\*\*](#t002fn004){ref-type="table-fn"}    24.1 ± 2.9[\*\*\*](#t002fn004){ref-type="table-fn"}    24.3 ± 2.9[\*\*\*](#t002fn004){ref-type="table-fn"}
  Proteinuria, first year         (+ or more, %)                               5.8           8.7[\*\*\*](#t002fn004){ref-type="table-fn"}           9.4[\*\*\*](#t002fn004){ref-type="table-fn"}           14.5[\*\*\*](#t002fn004){ref-type="table-fn"}
  Proteinuria, second year        (+ or more, %)                               6.0           7.4                                                    11.6[\*\*\*](#t002fn004){ref-type="table-fn"}          14.8[\*\*\*](#t002fn004){ref-type="table-fn"}
  Estimated GFR, first year       (ml/min/1.73 m^2^)                           79.9 ± 13.3   56.7 ± 4.3[\*\*\*](#t002fn004){ref-type="table-fn"}    67.2 ± 5.8[\*\*\*](#t002fn004){ref-type="table-fn"}    52.1 ± 7.2[\*\*\*](#t002fn004){ref-type="table-fn"}
  Estimated GFR, second year      (ml/min/1.73 m^2^)                           79.5 ± 13.2   66.7 ± 5.6[\*\*\*](#t002fn004){ref-type="table-fn"}    56.0 ± 4.4[\*\*\*](#t002fn004){ref-type="table-fn"}    51.3 ± 7.8[\*\*\*](#t002fn004){ref-type="table-fn"}
                                                                               Women                                                                                                                       
  Reduced eGFR category           (first measurement) / (second measurement)   (-) / (-)     (+) / (-)                                              (-) / (+)                                              (+) / (+)
  Study size                      (persons)                                    167328        7955                                                   8796                                                   14794
  Age                             (years)                                      63 ± 8        65 ± 6[\*\*\*](#t002fn004){ref-type="table-fn"}        65 ± 6[\*\*\*](#t002fn004){ref-type="table-fn"}        66 ± 6[\*\*\*](#t002fn004){ref-type="table-fn"}
  Systolic blood pressure         (mmHg)                                       127 ± 17      127 ± 17                                               130 ± 17[\*\*\*](#t002fn004){ref-type="table-fn"}      130 ± 17[\*\*\*](#t002fn004){ref-type="table-fn"}
  Diastolic blood pressure        (mmHg)                                       75 ± 11       75 ± 10[\*\*\*](#t002fn004){ref-type="table-fn"}       76 ± 10[\*\*\*](#t002fn004){ref-type="table-fn"}       76 ± 10[\*\*\*](#t002fn004){ref-type="table-fn"}
  Use of antihypertensive drugs   (%)                                          25.5          30.6[\*\*\*](#t002fn004){ref-type="table-fn"}          33.9[\*\*\*](#t002fn004){ref-type="table-fn"}          38.8[\*\*\*](#t002fn004){ref-type="table-fn"}
  Use of hypoglycemic drugs       (%)                                          3.4           3.6                                                    4.6                                                    5.37[\*\*\*](#t002fn004){ref-type="table-fn"}
  Triglycerides                   (mg/dl)                                      110 ± 64      115 ± 66[\*\*\*](#t002fn004){ref-type="table-fn"}      119 ± 70[\*\*\*](#t002fn004){ref-type="table-fn"}      121 ± 68[\*\*\*](#t002fn004){ref-type="table-fn"}
  Low-density lipoprotein         (mg/dl)                                      129 ± 30      133 ± 31[\*\*\*](#t002fn004){ref-type="table-fn"}      130 ± 31[\*\*](#t002fn003){ref-type="table-fn"}        131 ± 31[\*\*\*](#t002fn004){ref-type="table-fn"}
  High-density lipoprotein        (mg/dl)                                      65.5 ± 15.8   64.4 ± 16.0[\*\*\*](#t002fn004){ref-type="table-fn"}   63.8 ± 15.8[\*\*\*](#t002fn004){ref-type="table-fn"}   62.6 ± 15.4[\*\*\*](#t002fn004){ref-type="table-fn"}
  Use of lipid-lowering drugs     (%)                                          18.1          21.0[\*\*](#t002fn003){ref-type="table-fn"}            22.2[\*\*\*](#t002fn004){ref-type="table-fn"}          25.5[\*\*\*](#t002fn004){ref-type="table-fn"}
  Smoking                         (%)                                          5.3           4.1                                                    4.0[\*\*](#t002fn003){ref-type="table-fn"}             3.7[\*\*\*](#t002fn004){ref-type="table-fn"}
  Body mass index                 (kg/m^2^)                                    22.7 ± 3.4    23.0 ± 3.4[\*\*\*](#t002fn004){ref-type="table-fn"}    23.3 ± 3.4[\*\*\*](#t002fn004){ref-type="table-fn"}    23.4 ± 3.5[\*\*\*](#t002fn004){ref-type="table-fn"}
  Proteinuria, first year         (+ or more, %)                               2.9           4.5[\*\*\*](#t002fn004){ref-type="table-fn"}           4.5[\*\*\*](#t002fn004){ref-type="table-fn"}           8.8[\*\*\*](#t002fn004){ref-type="table-fn"}
  Proteinuria, second year        (+ or more, %)                               3.1           3.8                                                    5.9[\*\*\*](#t002fn004){ref-type="table-fn"}           8.9[\*\*\*](#t002fn004){ref-type="table-fn"}
  Estimated GFR, first year       (ml/min/1.73 m^2^)                           80.1 ± 14.4   54.5 ± 4.6[\*\*\*](#t002fn004){ref-type="table-fn"}    66.5 ± 6.5[\*\*\*](#t002fn004){ref-type="table-fn"}    51.3 ± 6.6[\*\*\*](#t002fn004){ref-type="table-fn"}
  Estimated GFR, second year      (ml/min/1.73 m^2^)                           79.7 ± 14.3   66.0 ± 6.5[\*\*\*](#t002fn004){ref-type="table-fn"}    54.4 ± 4.1[\*\*\*](#t002fn004){ref-type="table-fn"}    50.7 ± 7.1[\*\*\*](#t002fn004){ref-type="table-fn"}
  ------------------------------- -------------------------------------------- ------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------

Outliers of eGFR with less than 5 ml/min/1.73 m^2^ (N = 110) were excluded. The criterion of reduced eGFR was set at less than 60 ml/min/1.73 m^2^.

\*P\<0.05,

\*\*P\<0.01 and

\*\*\*P\<0.001.

Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.

There were 2,481 deaths, including 510 CVD deaths (20.6%) and 1,328 cancer deaths (53.5%) in the study period. When subdividing the subjects by proteinuria ([Table 1](#pone.0223005.t001){ref-type="table"}) and by renal function ([Table 2](#pone.0223005.t002){ref-type="table"}) with their variations between the first and second measurements, subjects with persistent proteinuria and with permanently reduced eGFR showed the highest or second highest mortality rate, as expected ([Table 3](#pone.0223005.t003){ref-type="table"}). Particularly between transient proteinuria (+/-) and newly developed proteinuria (-/+), the predominance of CVD mortality in transient proteinuria and that of cancer mortality in newly developed proteinuria seemed to be counterbalanced.

10.1371/journal.pone.0223005.t003

###### Crude all-cause and cause-specific mortalities of study subjects with and without definitive CKD.

![](pone.0223005.t003){#pone.0223005.t003g}

  Proteinuria category    (-) / (-)   (+) / (-)   (-) / (+)   (+) / (+)   
  ----------------------- ----------- ----------- ----------- ----------- ------------
  Men                                                                     
  Number                  123,248     5,347       5,750       4,828       
  All-cause               1,368       70          88          118         
  \%                      1.11        1.31        1.53        2.44        
  Cardiovascular          255         24          18          35          
  \%                      0.21        0.45        0.31        0.72        
  Cancer                  745         32          42          49          
  \%                      0.60        0.60        0.73        1.01        
  Women                                                                   
  Number                  186,957     4,521       4,877       2,566       
  All-cause               755         26          37          19          
  \%                      0.40        0.58        0.76        0.74        
  Cardiovascular          147         11          9           11          
  \%                      0.08        0.24        0.18        0.43        
  Cancer                  426         7           20          7           
  \%                      0.23        0.15        0.41        0.27        
  Reduced eGFR category   (-) / (-)   (+) / (-)   (-) / (+)   (+) / (+)   (Outliers)
  Men                                                                     
  Number                  107,261     6,596       7,637       17,617      
  All-cause               1,222       83          107         229         3
  \%                      1.14        1.26        1.40        1.30        
  Cardiovascular          233         22          16          61          0
  \%                      0.22        0.33        0.21        0.35        
  Cancer                  645         42          62          119         0
  \%                      0.60        0.64        0.81        0.68        
  Women                                                                   
  Number                  167,328     7,955       8,796       14,794      
  All-cause               667         36          36          98          0
  \%                      0.40        0.45        0.41        0.66        
  Cardiovascular          138         7           8           25          0
  \%                      0.08        0.09        0.09        0.17        
  Cancer                  370         21          21          48          0
  \%                      0.22        0.26        0.24        0.32        

Proteinuria was defined as 1+ or greater by dipstick tests. The criterion for reduced eGFR was set at less than 60 ml/min/1.73 m^2^. Excluding eGFR outliers (N = 110), three deaths could not be categorized. Abbreviations: eGFR, estimated glomerular filtration rate.

The HR for all-cause mortality was first examined in the total study population adjusted by age and sex ([Table 4](#pone.0223005.t004){ref-type="table"}). Newly developed proteinuria had a higher risk for all-cause mortality following persistent proteinuria, and significance remained after adjustment with covariates possibly related to mortality. On the other hand, the mortality risk with transient proteinuria was weaker and disappeared after adjustment with covariates. Regarding CKD with permanently reduced eGFR, weaker risks for all-cause mortality were shown with and without multivariable-adjustment. Both in subjects with transiently reduced eGFR and those with newly reduced eGFR, there was no significant risk for all-cause mortality ([Table 4](#pone.0223005.t004){ref-type="table"}).

10.1371/journal.pone.0223005.t004

###### Adjusted hazard ratios for all-cause mortality in this study population with and without CKD.

![](pone.0223005.t004){#pone.0223005.t004g}

  ----------------------------- --------------------------- ----------------------------------------------------- ------ -----------------------------------------------------
  Proteinuria                   Age-, sex- adjusted model   Multivariable-adjusted                                       
  Risk factor                   HR                          95% CI                                                HR     95% CI
  Age, +1 year                  1.07                        1.07--1.08[\*\*\*](#t004fn004){ref-type="table-fn"}   1.07   1.06--1.08[\*\*\*](#t004fn004){ref-type="table-fn"}
  Sex, women                    0.37                        0.34--0.40[\*\*\*](#t004fn004){ref-type="table-fn"}   0.45   0.41--0.49[\*\*\*](#t004fn004){ref-type="table-fn"}
  Proteinuria, (+)/(-)          1.30                        1.06--1.59[\*](#t004fn002){ref-type="table-fn"}       1.22   0.99--1.50
  Proteinuria, (-)/(+)          1.54                        1.29--1.85[\*\*\*](#t004fn004){ref-type="table-fn"}   1.42   1.19--1.70[\*\*\*](#t004fn004){ref-type="table-fn"}
  Proteinuria, (+)/(+)          2.23                        1.87--2.65[\*\*\*](#t004fn004){ref-type="table-fn"}   1.91   1.60--2.28[\*\*\*](#t004fn004){ref-type="table-fn"}
  Smoking, yes                                                                                                    1.74   1.58--1.92[\*\*\*](#t004fn004){ref-type="table-fn"}
  BMI, \>25 kg/m^2^                                                                                               1.03   0.94--1.13
  Untreated HTN                                                                                                   1.15   1.03--1.29[\*](#t004fn002){ref-type="table-fn"}
  Treated HTN                                                                                                     1.15   1.03--1.28[\*](#t004fn002){ref-type="table-fn"}
  HTN with treatment                                                                                              1.12   0.99--1.26
  Hypertriglyceridemia                                                                                            0.86   0.76--0.98[\*](#t004fn002){ref-type="table-fn"}
  High LDL                                                                                                        0.81   0.74--0.90[\*\*\*](#t004fn004){ref-type="table-fn"}
  Low HDL                                                                                                         1.46   1.28--1.68[\*\*\*](#t004fn004){ref-type="table-fn"}
  Use of lipid-lowering drugs                                                                                     0.97   0.86--1.09
  Use of hypoglycemic drugs                                                                                       1.60   1.40--1.84[\*\*\*](#t004fn004){ref-type="table-fn"}
  Reduced eGFR                  Age-, sex- adjusted model   Multivariable-adjusted                                       
  Risk factor                   HR                          95% CI                                                HR     95% CI
  Age, +1 year                  1.07                        1.07--1.08[\*\*\*](#t004fn004){ref-type="table-fn"}   1.08   1.07--1.08[\*\*\*](#t004fn004){ref-type="table-fn"}
  Sex, women                    0.36                        0.33--0.39[\*\*\*](#t004fn004){ref-type="table-fn"}   0.45   0.41--0.49[\*\*\*](#t004fn004){ref-type="table-fn"}
  Low eGFR, (+)/(-)             0.98                        0.82--1.18                                            1.01   0.84--1.22
  Low eGFR, (-)/(+)             1.12                        0.94--1.33                                            1.11   0.93--1.31
  Low eGFR, (+)/(+)             1.13                        1.003--1.27[\*](#t004fn002){ref-type="table-fn"}      1.13   1.004--1.28[\*](#t004fn002){ref-type="table-fn"}
  Smoking, yes                                                                                                    1.78   1.62--1.97[\*\*\*](#t004fn004){ref-type="table-fn"}
  BMI, \>25 kg/m^2^                                                                                               1.05   0.96--1.15
  Untreated HTN                                                                                                   1.17   1.05--1.31[\*\*](#t004fn003){ref-type="table-fn"}
  Treated HTN                                                                                                     1.18   1.06--1.31[\*\*](#t004fn003){ref-type="table-fn"}
  HTN with treatment                                                                                              1.17   1.04--1.32[\*](#t004fn002){ref-type="table-fn"}
  Hypertriglyceridemia                                                                                            0.87   0.77--0.99[\*](#t004fn002){ref-type="table-fn"}
  High LDL                                                                                                        0.82   0.74--0.90[\*\*\*](#t004fn004){ref-type="table-fn"}
  Low HDL                                                                                                         1.46   1.27--1.68[\*\*\*](#t004fn004){ref-type="table-fn"}
  Use of lipid-lowering drugs                                                                                     0.97   0.87--1.09
  Use of hypoglycemic drugs                                                                                       1.70   1.48--1.94[\*\*\*](#t004fn004){ref-type="table-fn"}
  ----------------------------- --------------------------- ----------------------------------------------------- ------ -----------------------------------------------------

Hazard ratios and 95% confidence intervals adjusted by age and sex, and by multiple variables, respectively. They are compared with definitely negative proteinuria (-)/(-) or with definitely not reduced eGFR (-)/(-) as the reference. The criterion of reduced eGFR was set at less than 60 ml/min/1.73 m^2^.

\**P*\<0.05,

\*\**P*\<0.01, and

\*\*\**P*\<0.001.

Abbreviations: CKD, chronic kidney disease; HTN, hypertension; LDL, Low-density lipoprotein; HDL, High-density lipoprotein; eGFR, estimated glomerular filtration rate.

[Fig 2](#pone.0223005.g002){ref-type="fig"} shows the HRs for all-cause mortality, CVD mortality, and cancer mortality, the leading causes of death in this study population. In men and in women, the HR for all-cause mortality was significant for newly developed proteinuria and for persistent proteinuria and not significant for transient proteinuria. The HR for CVD mortality was significantly higher for transient proteinuria (1.94 \[95%CI 1.27--2.96\] in men and 2.78 \[1.50--5.16\] in women) than for newly developed proteinuria (1.32 \[0.81--2.13\] in men and 2.04 \[1.04--4.01\] in women). On the other hand, the HR for cancer mortality for transient proteinuria was not significant and tended to be lower (0.99 \[0.70--1.42\] in men and 0.70 \[0.33--1.48\] in women) than that for newly developed proteinuria (1.17 \[0.85--1.59\] in men and 1.79 \[1.14--2.82\] in women).

![Multiply adjusted hazard ratios for cause-specific mortality with and without CKD determined by proteinuria.\
Symbol and error bars indicate multiply adjusted hazard ratios and 95% confidence intervals compared to definitely negative proteinuria (-)/(-) as the reference. Analyses are performed by sex; therefore, corresponding variables are similar to [Table 4](#pone.0223005.t004){ref-type="table"}, except for sex. Abbreviations: CVD, cardiovascular diseases.](pone.0223005.g002){#pone.0223005.g002}

Regarding mortality risk with reduced eGFR, in women, the HR for all-cause mortality was significant with a permanently reduced eGFR less than 60 ml/min/1.73 m^2^, and it was not significant with a transiently reduced eGFR ([Fig 3](#pone.0223005.g003){ref-type="fig"}). In the same way, the HRs for CVD mortality and cancer mortality were significantly higher only with permanently reduced eGFR. Though there were no significant risks for all-cause mortality in men in [Fig 3](#pone.0223005.g003){ref-type="fig"}, a permanently reduced eGFR below 45 ml/min/1.73 m^2^ had a significant risk for all-cause mortality ([S1 Fig](#pone.0223005.s001){ref-type="supplementary-material"}). Moreover, a transiently reduced eGFR below 45 ml/min/1.73 m^2^ was not significantly associated with the risk for CVD mortality.

![Multiply adjusted hazard ratios for cause-specific mortality with and without CKD determined by eGFR 60 ml/min/1.73 m^2^.\
Symbol and error bars indicate multiply adjusted hazard ratios and 95% confidence intervals compared to definitely without reduced eGFR (-)/(-) as the reference. Analyses are performed by sex, therefore, corresponding variables are similar to [Table 4](#pone.0223005.t004){ref-type="table"}, except for sex. Abbreviations: CVD, cardiovascular diseases. eGFR, estimated glomerular filtration rate.](pone.0223005.g003){#pone.0223005.g003}

Discussion {#sec008}
==========

The present study demonstrated that a general population with transient dipstick proteinuria (1+ or more) had an increased risk for CVD mortality, while that with transiently reduced eGFR less than 60 ml/min/1.73 m^2^ did not have any increased risk for mortality in a longitudinal cohort of 338,094 persons from the general population with two or more assessments both of proteinuria and of renal function for dealing with metabolic syndrome as "Specific Health Check and Guidance". As far as we know, there have been few attempts to assess cause-specific mortality related to changes in urinary albumin and protein levels in observational study settings. The Stockholm CREAtinine Measurements (SCREAM) project is a healthcare utilization study that contains 31,732 individuals with two or more ACR tests \[[@pone.0223005.ref019]\]. In this cohort, an ACR increase was associated with mortality, but the relationship was largely flat for an ACR decline. When focusing on cause-specific mortality, a 4-fold decrease in ACR tended to be associated with a higher risk for CVD mortality (HR \[95%CI\]; 1.35 \[0.93--1.95\]), while the HR for non-CVD mortality was not higher (0.89 \[0.67--1.18\]). This motivated us to examine the significance of transient proteinuria for CVD mortality in our large-sized study cohort.

Subjects with transient proteinuria or transiently reduced eGFR generally have worse co-morbid conditions (hypertension, use of hypoglycemic drugs, and lipid status) and worse physical status (higher BMI) compared to definitely negative proteinuria or definitely not reduced eGFR ([Table 1](#pone.0223005.t001){ref-type="table"}), respectively. As a consequence, a higher crude-death rate was demonstrated ([Table 3](#pone.0223005.t003){ref-type="table"}) comparing negative proteinuria or preserved eGFR, and adjusting for age and covariates was necessary to assess mortality risk ([Table 4](#pone.0223005.t004){ref-type="table"}). Even if a prior study \[[@pone.0223005.ref019]\] and the present study were taken together, it is difficult to explain why decreases in urinary albumin and protein were involved in increased CVD mortality during the study follow-up period. One possibility as a cause for the higher CVD mortality risk with transient proteinuria compared to newly developed proteinuria may have been information that was not available in this study, such as prior development of proteinuria before 2008 at the starting year. However, this phenomenon does not conflict with the findings of prior randomized, controlled studies, because they compared placebo-adjusted treatment effects on the decline in albuminuria as clinical endpoints \[[@pone.0223005.ref027]--[@pone.0223005.ref029]\] that had comparable proteinuria levels at baseline, completely apart from the general population setting of the present study.

On the other hand, a decreased eGFR becomes a promising clinical endpoint because it can be a risk for the incidence of ESKD and the incidence and mortality of CVD \[[@pone.0223005.ref010]--[@pone.0223005.ref017]\]. Decline in eGFR in CKD and non-CKD patients should be assessed for the risk of incident and of all-cause mortality because the eGFR slope in CKD subjects with low-eGFR is much more significant and sensitive compared to that in subjects without low-eGFR \[[@pone.0223005.ref030]\]. Though the cut-off values of eGFR are flexible to assess the risk for mortality (\<60 in [Fig 3](#pone.0223005.g003){ref-type="fig"} and \<45 ml/min/1.73 m^2^ in [S1 Fig](#pone.0223005.s001){ref-type="supplementary-material"}, were applied), as expected based on previous reports \[[@pone.0223005.ref010]--[@pone.0223005.ref014]\], newly reduced eGFR (-11.2 in men and -12.1 ml/min/1.73 m^2^ in women between two measurements) had a significant risk for all-cause mortality, as well as permanently decreased eGFR. Since some of these investigations also found a higher risk for mortality in a population with increased eGFR, it had been speculated that transiently reduced eGFR had a small risk for CVD mortality as well. However, at least there is no increased risk with transiently reduced eGFR compared to newly reduced eGFR, unlike in the context of proteinuria.

Transiently reduced eGFR might occur with some reasons, such as recovery from kidney injury, reduction of muscle mass, increased body fluid concentration due to participants' fasting before blood test as well as transient proteinuria occurs. These mechanisms were supported by frequency of proteinuria decreased between first year and second year (8.7% to 7.4% in men and 4.5% to 3.8% in women, [Table 2](#pone.0223005.t002){ref-type="table"}). However our current analyses could not conclude how come there is a different trend in risk for CVD mortality between in transient proteinuria and in transiently reduced eGFR. We further tried to elucidate risk in conjunction of transient proteinuria and transiently reduced eGFR ([S2 Fig](#pone.0223005.s002){ref-type="supplementary-material"}). Though number of CVD death was too small to make a conclusion, the result implied coincidence of transient proteinuria and reduced eGFR was also significant risk of CVD mortality but not non-CVD mortality (CVD; 3.12 \[1.78--5.46\] in men and 3.97 \[1.46--10.76\] in women).

As the scope of the present report was to elucidate the importance of transient proteinuria in cause-specific death, cancer mortality, as the leading cause of non-CVD death, was used just as the analytical control. Though the results shown in this article might partly contribute to promote the research field of cancer biology and epidemiology, more detailed analyses regarding the relationship between cancer and CKD have been in progress and will be reported by our group with a different methodology and a different study population from the screened subjects (*Tsuruya et al*. *in preparation*).

To the best of our knowledge, this is the first study to examine a large-sized (over 100,000 subjects) general population with both transient dipstick proteinuria and transiently reduced renal function and reliable death registration. Therefore, the strategy had the strength to perform sub-analyses of men or women enrolled and to detect cause-specific death. Moreover, dipstick proteinuria was routinely examined in the healthcheck, unlike ACR, which is not routinely tested with some healthcare policies. However, this study also has several limitations. First, the results of semi-quantitative dipstick proteinuria cannot be corrected by urinary creatinine and are affected by urinary concentration that might provide functional, pseudo-positive proteinuria. Second, the measurement of biochemical parameters including proteinuria and serum creatinine to determine subcategories was performed only once per year. Mortality rate in this cohort was not so high because of relatively shorter observational interval (4.2±1.3 years) and relatively younger population (63.2±7.8 years old at baseline). It was not possible to clarify what kind of specific intervention was performed in transient proteinuria from the first measurement, such as use of renin-angiotensin system inhibitors, which is necessary information to clarify the mechanisms of decreased proteinuria.

Conclusion {#sec009}
==========

From this study, transient proteinuria in the general population appears to be a significant risk factor specifically for CVD mortality, but not for non-CVD mortality. The association between transiently reduced eGFR and mortality is weaker, while permanently reduced eGFR clearly shows a higher HR for mortality, as expected. This appears to be the first study examining the mortality risk of transient dipstick proteinuria using a large-sized general population cohort with cause-specific death registration.

Supporting information {#sec010}
======================

###### Multiple-adjusted hazard ratios for all-cause mortality and cause-specific mortality with and without advanced CKD determined by eGFR 45 ml/min/1.73m^2^.

Symbol and error bars indicate multiple variable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) comparing to definitely without Low eGFR less than 45 ml/min/1.73m^2^ (-)/(-) as reference. Analyses were performed by sex, therefore, corresponding variables are similar to [Table 4](#pone.0223005.t004){ref-type="table"}, except for sex. Abbreviations: CVD, cardiovascular diseases. eGFR, estimated glomerular filtration ratio.

(PDF)

###### 

Click here for additional data file.

###### Multiple variable-adjusted hazard ratios for all-cause mortality and cause-specific mortality with and without proteinuria and low eGFR.

Symbol and error bars indicate multiple variable-adjusted hazard ratios (HRs) and 95% confidence intervals comparing to definitely without proteinuria or Low eGFR less than 60 ml/min/1.73 m2 (-)/(-) as reference. Analyses were performed by sex, therefore, corresponding variables are similar to [Table 4](#pone.0223005.t004){ref-type="table"}, except for sex. Abbreviations: CVD, cardiovascular diseases. eGFR, estimated glomerular filtration ratio.

(PDF)

###### 

Click here for additional data file.
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